TY - JOUR
T1 - Ivabradine
T2 - Heart failure and beyond
AU - Chaudhary, Rahul
AU - Garg, Jalaj
AU - Krishnamoorthy, Parasuram
AU - Shah, Neeraj
AU - Lanier, Gregg
AU - Martinez, Mathew W.
AU - Freudenberger, Ronald
N1 - Publisher Copyright:
© The Author(s) 2015.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2016/7
Y1 - 2016/7
N2 - Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current (If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative inotropic effect. Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure. This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths. Additionally, ivabradine has been associated with reduced cardiac remodeling, reduced heart rate variability, improvement in exercise tolerance, improved heart failure class of New York Heart Association, and better quality of life. It has also been tried in other conditions, such as inappropriate sinus tachycardia and cardiogenic shock, and is currently in phase II trial for patients with newly diagnosed multiple organ dysfunction syndrome.
AB - Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current (If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative inotropic effect. Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure. This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths. Additionally, ivabradine has been associated with reduced cardiac remodeling, reduced heart rate variability, improvement in exercise tolerance, improved heart failure class of New York Heart Association, and better quality of life. It has also been tried in other conditions, such as inappropriate sinus tachycardia and cardiogenic shock, and is currently in phase II trial for patients with newly diagnosed multiple organ dysfunction syndrome.
KW - Funny current
KW - HCN
KW - Heart failure
KW - Ivabradine
KW - SHIFT
KW - SIGNIFY
UR - http://www.scopus.com/inward/record.url?scp=84978872856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978872856&partnerID=8YFLogxK
U2 - 10.1177/1074248415624157
DO - 10.1177/1074248415624157
M3 - Article
C2 - 26721645
AN - SCOPUS:84978872856
SN - 1074-2484
VL - 21
SP - 335
EP - 343
JO - Journal of Cardiovascular Pharmacology and Therapeutics
JF - Journal of Cardiovascular Pharmacology and Therapeutics
IS - 4
ER -